Mean Platelet Volume in Ocular Behçet’s Disease

Objective. To determine whether mean platelet volume (MPV) is an indicator of disease severity in ocular Behçet’s Disease (BD). Materials and Methods. The study population was 30 newly diagnosed ocular BD patients who presented with active uveitis. These patients had no past history of smoking, drug...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:TheScientificWorld 2013-01, Vol.2013 (2013), p.1-4
Hauptverfasser: Çaça, İhsan, Özkurt, Zeynep, Şahin, Muhammed, Akkurt, Meltem, Çınar, Yasin, Yüksel, Harun, Cingü, Abdullah Kürşat, Türkcü, Fatih Mehmet, Şahin, Alparslan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective. To determine whether mean platelet volume (MPV) is an indicator of disease severity in ocular Behçet’s Disease (BD). Materials and Methods. The study population was 30 newly diagnosed ocular BD patients who presented with active uveitis. These patients had no past history of smoking, drug use, or systemic diseases including diabetes mellitus, hypertension, cardiovascular disease, and renal disease. A control group consisting of 34 healthy individuals was included for comparison. MPV measurements were performed serially upon presentation with active uveitis and at one and three month thereafter in BD group whereas only at presentation in the controls. Results. Upon presentation with active uveitis, the mean MPV levels were 7.88 ± 1.14 femtoliters (fL) for BD group. During the posttreatment follow-up period at first and third months, BD patients demonstrated a mean MPV level of 7.71 ± 1.12 fL and 7.65 ± 1.04 fL, respectively. The mean MPV value of control group, was 8.39 ± 0.66 fL at presentation. Fluctuations in MPV values were not significant in the BD group, while there was a significant difference between the initial measurements of the BD and control groups. Conclusion. MPV measurement in ocular BD is not a predictive laboratory test to determine the clinical improvement in early stages following classical immunosuppressive treatment.
ISSN:2356-6140
1537-744X
1537-744X
DOI:10.1155/2013/215912